Please login to the form below

Not currently logged in
Email:
Password:

Revolution Medicines appoints Dr Stephen Kelsey

He joins the firm from Onkaido Therapeutics

Dr Stephen KelseyRevolution Medicines has appointed Dr Stephen Kelsey as its senior leader in a role that will see him focus on advancing medical agendas to aid cancer patients.

Most recently president at Onkaido Therapeutics, Kelsey’s specialty lies within oncology and development.

He said: “Revolution Medicines uses a novel approach to drug discovery that enables it to tackle promising cancer targets that have been difficult to access by convention means.

“I’m impressed with the quality of the company’s research team, founders and advisors, and am keen to help bring the next generation of transformational therapeutics to cancer patients.”

Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.

Mark Goldsmith, president and chief executive officer of Revolution Medicines, said: “Steve has had a distinguished career in oncology as both an academic clinician and a drug development executive in the biotechnology industry.

“He is superbly positioned to help us by deliver great benefit to cancer patients by advancing our lead programmes and creating a sustainable product pipeline that harnesses frontier oncology targets.”

31st March 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics